Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors’ Expert Forum

In December 2008, the U.S. Food and Drug Administration issued guidance to the pharmaceutical industry setting new expectations for the development of antidiabetes drugs for type 2 diabetes. This guidance expanded the scope and cost of research necessary for approval of such drugs by mandating long-...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Diabetes Care
Autors principals: Cefalu, William T., Kaul, Sanjay, Gerstein, Hertzel C., Holman, Rury R., Zinman, Bernard, Skyler, Jay S., Green, Jennifer B., Buse, John B., Inzucchi, Silvio E., Leiter, Lawrence A., Raz, Itamar, Rosenstock, Julio, Riddle, Matthew C.
Format: Artigo
Idioma:Inglês
Publicat: American Diabetes Association 2018
Matèries:
Diabetes Care Expert Forum
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5741160/
https://ncbi.nlm.nih.gov/pubmed/29263194
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dci17-0057
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars